Literature DB >> 20386450

Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin infections.

Christine A Odell1.   

Abstract

PURPOSE OF REVIEW: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has become increasingly important as a cause of skin and soft tissue infections (SSTIs), particularly abscesses, in patients seen in the emergency department setting. The antibiotic sensitivity profile of Staphylococcus aureus isolates from SSTIs has changed over time in many geographic locations. Whether antibiotics are needed in the management of skin abscesses, and, if so, when, is controversial. RECENT
FINDINGS: A number of studies have looked at antibiotic therapy in conjunction with incision and drainage in managing abscesses. Factors evaluated were resolution of infection, need for change in antibiotic therapy, hospitalization after initial outpatient management, need for an additional drainage procedure, and recurrence of infection within 30 days after the initial incision and drainage procedure. For abscesses, clinical failure was associated with lack of adequate incision and drainage and not antibiotic use, regardless of the size of the abscess or the choice of antibiotic therapy. For other soft tissue infections, when antibiotic susceptibility data were available for the infection (impetigo or cellulitis with purulent drainage but no abscess), there was no difference in clinical resolution of MRSA infection even if the infecting organism was resistant to the antibiotic chosen for therapy.
SUMMARY: CA-MRSA has become an important cause of SSTIs. Current data suggest that most abscesses can be treated successfully with incision and drainage alone. Antibiotic choice is more crucial for management of cellulitis and should be guided by the prevalence of CA-MRSA in the community and its antibiotic susceptibility profile.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20386450     DOI: 10.1097/MOP.0b013e328339421b

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  15 in total

Review 1.  Novel antiangiogenic agents in dermatology.

Authors:  Ricardo L Berrios; Jack L Arbiser
Journal:  Arch Biochem Biophys       Date:  2010-12-21       Impact factor: 4.013

Review 2.  Mastitis therapy and antimicrobial susceptibility: a multispecies review with a focus on antibiotic treatment of mastitis in dairy cattle.

Authors:  John Barlow
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-10-09       Impact factor: 2.673

Review 3.  Resistant pathogens, fungi, and viruses.

Authors:  Christopher A Guidry; Sara A Mansfield; Robert G Sawyer; Charles H Cook
Journal:  Surg Clin North Am       Date:  2014-10-03       Impact factor: 2.741

4.  Vancomycin Use in Patients Discharged From the Emergency Department: A Retrospective Observational Cohort Study.

Authors:  Kristen Mueller; Craig McCammon; Lee Skrupky; Brian M Fuller
Journal:  J Emerg Med       Date:  2015-03-21       Impact factor: 1.484

5.  Synthesis and antibacterial evaluation of a novel series of synthetic phenylthiazole compounds against methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Haroon Mohammad; P V Narasimha Reddy; Dennis Monteleone; Abdelrahman S Mayhoub; Mark Cushman; Mohamed N Seleem
Journal:  Eur J Med Chem       Date:  2015-03-07       Impact factor: 6.514

6.  Blue light eliminates community-acquired methicillin-resistant Staphylococcus aureus in infected mouse skin abrasions.

Authors:  Tianhong Dai; Asheesh Gupta; Ying-Ying Huang; Margaret E Sherwood; Clinton K Murray; Mark S Vrahas; Tammy Kielian; Michael R Hamblin
Journal:  Photomed Laser Surg       Date:  2013-02-13       Impact factor: 2.796

7.  Emergency Department vancomycin use: dosing practices and associated outcomes.

Authors:  Brian M Fuller; Nicholas Mohr; Lee Skrupky; Kristen Mueller; Craig McCammon
Journal:  J Emerg Med       Date:  2012-12-21       Impact factor: 1.484

Review 8.  Antimicrobial peptides and peptidomimetics - potent therapeutic allies for staphylococcal infections.

Authors:  Haroon Mohammad; Shankar Thangamani; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

9.  Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections.

Authors:  Shankar Thangamani; Waleed Younis; Mohamed N Seleem
Journal:  Sci Rep       Date:  2015-06-26       Impact factor: 4.379

10.  Fermentation of Propionibacterium acnes, a commensal bacterium in the human skin microbiome, as skin probiotics against methicillin-resistant Staphylococcus aureus.

Authors:  Muya Shu; Yanhan Wang; Jinghua Yu; Sherwin Kuo; Alvin Coda; Yong Jiang; Richard L Gallo; Chun-Ming Huang
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.